Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS

This article was originally published in The Pink Sheet Daily

Executive Summary

The device is one the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.


Related Content

St. Jude Plans Trial To Study Renal Denervation Outcomes
Boston Scientific Enters Renal Denervation Market Via Vessix Acquisition
CDRH Entrepreneurs Take Two: Streamlining Data Collection And The Path To Reimbursement
CMS Policy Sets Boundaries On Transcatheter Valve Procedure
Calling All Innovators: FDA And CMS Seek Candidates For Parallel Review Pilot
With Trial Approval, Medtronic Aims For Symplicity RF Catheter Launch In 2014
Cypher’s Impact On Regulatory, Reimbursement Landscape
Parallel Reviews Should Lead To Local Coverage, Coding Decisions, Firms Say
Ablating Blood Pressure: Ardian's RF Catheter Hits Hypertension Endpoint
FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts